Login to Your Account

CFDA clears phase III trial of oncolytic immunotherapy from Lee's, Sillajen

By Cornelia Zou
Staff Write

Monday, July 24, 2017

HONG KONG – The Chinese drug registration authority has approved the phase III trial of a cancer drug in the first open meeting it ever held, clearing the way for late-stage testing of an oncolytic immunotherapy drug developed by Korean biopharma company Sillajen Inc. and its Chinese partner, Lee's Pharmaceutical Holdings Ltd.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription